You are here
Preclinical Working Group
On this page
Standardize and share preclinical evaluation resources and methods and accelerate testing of candidate therapies and vaccines to support entry into clinical trials.
Check mark indicates completion.
✓ Preclinical Resource Map
The working group has developed a master inventory of preclinical testing resources, including for nonhuman primates (NHPs), small animal models, and biosafety level 3/4 laboratories. To facilitate up-to-date information on this inventory of testing resources, the working group created a web-based form to use for collection of data on facilities that can carry out SARS-CoV-2 assays and animal models. The collection of this information is aiding in standardization of animal model testing efforts.
✓ National Strategy for NHP Preclinical Resources
The working group has helped develop a strategy for COVID-19-related NHP studies, in collaboration with the National Primate Research Centers, which aims to maximize the research value of scarce NHP resources that are needed to test vaccines and certain therapeutics during the pandemic. The strategy includes:
- A staged approach for animal use aligned with immediate need
- Defined points of interaction between an ACTIV expert panel and the National Primate Research Center directors
- Recommended clear guidance for animal use and therapeutic testing, including the first ever master protocol for non-human primate research
✓ Pandemic Response Framework
- The working group has developed “Pandemic Mode” operating procedures for accelerated preclinical agent development, including antivirals, immunomodulators, and anticoagulants. The approach to accelerated therapeutic development focuses on critical path activities to capture key aspects of efficacy and safety, as shown in the figure below. This approach is most easily associated with therapeutics that already have clinical data in another therapeutic area.
Preclinical Testing Network
The working group is in the process of creating a virtual testing network of biosafety level 3/4 laboratories for triaged drug candidates. The sites that will be needed are those that can carry out the essential experiments that have been described in the Pandemic Mode process and could rapidly deploy clinical testing in COVID-19 patients.
✓ Preclinical Prioritization
The working group has completed a prioritization framework, using the “Pandemic Mode” procedures described above as a basis, for evaluating and prioritizing preclinical compounds for further preclinical testing. The compounds that have been submitted to ACTIV for review are being evaluated for further preclinical development with the expectation that they may proceed into one of the ACTIV clinical master protocols (see Therapeutics Clinical Working Group).
✓ Preclinical Compound Survey
To assist in developing and prioritizing a complete inventory of potential candidates with different approaches to preventing or mitigating COVID-19 infection, an ACTIV COVID-19 Clinical & Preclinical Candidate Compound Survey has been established in conjunction with the Therapeutics Clinical Working Group. The survey collects detailed information from sponsors such as preclinical and clinical data on therapeutic candidates. Stakeholders throughout the biopharmaceutical, academic, scientific research, advocacy, and clinical practice communities are welcome to participate in the survey.
✓ Preclinical Data Sharing
The working group is creating a public database for sharing preclinical data using the NCATS OpenData Portal. Importantly, the portal will allow for both the comprehensive sharing of data as well as information on how the data were generated. This will facilitate interpretation and comparison of results from multiple experiments on multiple agents that could provide insight on SARS-CoV-2 and treatment approaches not apparent from a single study.
Animal model summaries, field guides, and additional resources have been curated and released on the NCATS OpenData Portal. Additional information will continue to be added as it becomes available.
This page last reviewed on December 23, 2020